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Guinea in the era of conjugate vaccines:
study methods and challenges
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Lapule Yuasi4, Andrew Greenhill4,5, Ilomo Hwaihwanje6, Amanda Lang4, Deborah Lehmann2,4, William Pomat2,4
on behalf of the Papua New Guinea Pneumonia and Meningitis Etiology Study TeamAbstract
Background: Pneumonia and meningitis are common causes of severe childhood illness in Papua New Guinea
(PNG). The etiology of both clinical conditions in PNG has not been recently assessed. Changes in lifestyle, provision
and access to healthcare, antimicrobial utilization and resistance, and the national childhood vaccination schedule
necessitate reassessment.
Methods: A prospective case-control study was undertaken, enrolling children <5 years of age to determine the
contemporary etiology of clinically defined moderate or severe pneumonia or suspected meningitis. Cases were
identified following presentation for inpatient or outpatient care in Goroka town, the major population centre in
the Eastern Highlands Province. Following enrolment, routine diagnostic specimens including blood, nasopharyngeal
swabs, urine and (if required) cerebrospinal fluid, were obtained. Cases residing within one hour’s drive of Goroka were
followed up, and recruitment of healthy contemporaneous controls was undertaken in the cases’ communities.
Results: 998 cases and 978 controls were enrolled over 3 years. This included 784 cases (78.6%) with moderate
pneumonia, 187 (18.7%) with severe pneumonia and 75 (7.5%) with suspected meningitis, of whom 48 (4.8%) had
concurrent pneumonia. The median age of cases was 7.8 months (Interquartile range [IQR] 3.9–14.3), significantly
lower than community controls, which was 20.8 months (IQR 8.2–36.4). Half the cases were admitted to hospital
(500/998; 50.1%). Recruitment of cases and controls and successful collection of diagnostic specimens improved
throughout the study, with blood volume increasing and rates of blood culture contamination decreasing. The
overall case fatality rate was 18/998 (1.8%). Of cases eligible for follow-up, outcome data was available from 76.7%. Low
but increasing coverage of Haemophilus influenzae type B conjugate vaccines on the national schedule was observed
during the study period: three dose DTPw-HepB-Hib coverage in children >3 months increased from 14.9 to 43.0% and
29.0 to 47.7% in cases and controls (both p < 0.001). Despite inclusion in the national immunization program in 2014,
2015 PCV13 three-dose coverage in cases and controls >3 months was only 4.0 and 6.5%.
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Conclusions: Recruitment of large numbers of pediatric pneumonia and meningitis cases and community
controls in a third-world setting presents unique challenges. Successful enrolment of 998 cases and 978 controls
with comprehensive clinical data, biological specimens and follow up was achieved. Increased vaccine coverage
remains an ongoing health priority.
Keywords: Pneumonia, Meningitis, Papua New Guinea, Streptococcus pneumoniae, Haemophilus influenzae, VaccinationBackground
Pneumonia and meningitis are common childhood dis-
eases, resulting in significant morbidity and mortality
among young children [1]. It is estimated that acute
lower respiratory tract infection results in approximately
2.7 million deaths per annum, with 50% occurring in
children <5 years of age. Of childhood pneumonia
deaths, 33 and 16% are attributable to Streptococcus
pneumoniae and Haemophilus influenzae, respectively
[1]. Meningitis is estimated to result in >300,000 deaths
(all ages) globally, with 26 and 21% estimated to be
caused by S. pneumoniae and H. influenzae [1].
Papua New Guinea (PNG) was previously identified as
a high priority country for the achievement of the
United Nations Millennium Development Goals because
the baseline child mortality rate is among the highest in
the Western Pacific Region (<5 year old mortality rate in
2015: 57 per 1000 live births [2]). Pneumonia and men-
ingitis are the most common causes for childhood
deaths reported to the National Health Information
Systems [3, 4]. Studies conducted in the Asaro Valley,
including Goroka town, the provincial capital of Eastern
Highlands Province (EHP), have repeatedly demon-
strated the importance of S. pneumoniae and H. influen-
zae in the etiology of pneumonia and meningitis [5–11].
There are a paucity of contemporary data examining the
bacterial causes of pneumonia and meningitis: the only
recent study used opportunistically collected cerebro-
spinal fluid (CSF) samples from children admitted to
Goroka General Hospital (GGH; 1996–2005) [9]. The
current contribution of respiratory viruses to pneumonia
also remains uncertain; apart from a single study asses-
sing respiratory viruses in infants enrolled in a neonatal
pneumococcal conjugate vaccine trial [12], prospective
studies have not been undertaken since 1985 [13].
Conjugate H. influenzae type B (Hib) vaccine and 13-
valent S. pneumoniae vaccine (13vPCV) were introduced
into the national vaccination schedule in 2008 and 2014,
respectively. From 2014, PNG infants were recom-
mended neonatal BCG and hepatitis B vaccines followed
by diphtheria, tetanus, whole-cell pertussis, hepatitis B
and Hib vaccine (DTPw-HepB-Hib), 13vPCV and oral
polio vaccines at 1, 2 and 3 months of age. Routine mea-
sles vaccines were recommended at 6 and 9 months[14]. In 2015, the PNG National Department of Health
launched a Special Integrated Routine EPI Strengthening
Program (SIREP Plus), a multimodal program aimed at
improving coverage of vaccines already provided free
under the national immunization program as well as
introducing measles-rubella (MR, recommended at 6, 9
and 18 months) and inactivated polio vaccine (IPV, at
3 months) to all PNG children, and PCV13 to provinces
yet to introduce the vaccine. Despite the 2014 launch,
PCV13 was not available for use in children in the PNG
highlands until 2015.
Given these changes, determining vaccine coverage in
the PNG highlands and assessing the contemporary eti-
ology of pneumonia and meningitis is a research priority.
Commencing in 2013, we conducted a prospective case-
control study enrolling children with clinically-defined
moderate or severe pneumonia or suspected meningitis
(cases) and contemporaneous community controls. This
article describes the study methodology, population, vac-
cine coverage, and some of the operational and logistical
challenges encountered throughout this study.Methods
We performed a prospective case-control study recruit-
ing children with clinical pneumonia and/or suspected
meningitis presenting either to the Eastern Highlands
Provincial Hospital (EHPH, previously known as the
Goroka General Hospital, GGH) or community health-
care clinics elsewhere in Goroka town and contempor-
aneous healthy community controls (January 2013 to
January 2016). The date of commencement was chosen
to ensure sufficient recruitment prior to the national
introduction of the 13vPCV.
The study aims were to: (i) determine the etiology of
pneumonia and meningitis in a setting with previously
reported high rates of both diseases; (ii) identify the se-
rotypes of S. pneumoniae causing invasive disease; (iii)
determine the antimicrobial susceptibility profiles of iso-
lated bacterial pathogens; (iv) examine the utility of mo-
lecular and other diagnostic assays in PNG children with
pneumonia and meningitis and (v) explore clinical and
laboratory variables associated with specific pathogens
and severe diseases.
Table 1 Inclusion and exclusion criteria including clinical case
definitions [14]
Criteria Classification Definitions
Inclusion
Criteria
(cases)
Moderate
pneumonia
Presence of all three symptoms and signs:
• cough
• tachypnoea rate (≥60/min if <2 months,
≥40/min if ≥2 mo of age)
• lower chest wall indrawing
Severe
pneumonia
Moderate pneumonia with one of the
following added features:
• pulse >160/min with hepatomegaly
>2 cm below costal margin
• cyanosed or restless
• inability to breastfeed/drink or vomiting.
Suspected
meningitis
Defined by the presence of fever (>37.5 °C)
and one of the following additional features:
• seizures
• impaired or altered consciousness
• irritability
• a bulging fontanelle
• signs of meningeal irritation
(e.g. neck stiffness, Kernig’s sign).
Exclusion criteria (cases) The following children were excluded from
enrolment as cases:
• age≥ 5 years
• severe congenital abnormality
• hospitalisation in preceding 14 days
• previous enrolment as either case or
control in the study within 30 days
• parent unable or unwilling to give consent
Exclusion criteria
(controls)
The following children were excluded
from enrolment as controls
• age≥ 5 years
• symptoms or signs of active infection
including cough, tachypnoea, lower chest
wall indrawing, fever (>37.5 °C), altered
consciousness, drowsy or “staring eyes”,
irritability, bulging fontanelle and neck
stiffness or signs of meningeal irritation
• severe congenital abnormality
• hospitalization in preceding 14 days
• previous enrolment in the study as a controla
• exposed to antibiotics in the past 30 days
• parent unable or unwilling to give consent
Abbreviations: Mo months
a Controls could be subsequently enrolled as cases if more than 30 days since
previous enrolment
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The study was conducted in the EHP of PNG, an area of
11,157 km2, located at 6030’S 145040’E with a population
of 579,825 (2011 census) [15]. Goroka, the provincial
capital of EHP (population of 23,277) is located 1600 m
above sea level, is only accessible by air from the na-
tional capital Port Moresby, and by a narrow mountain-
ous highway to the nearest sea port, Lae. Sealed roads
exist between major centres, but are often in poor con-
dition. Feeder roads to villages are generally unsealed
tracks and many villages and hamlets are only access-
ible on foot. Living standards vary significantly. In rural
areas people live in hamlets in traditional thatched
houses and are primarily subsistence farmers, but may
obtain cash through sales of coffee and market produce.
In the urban and peri-urban areas, many houses are
built with strong and long-lasting materials such as an
iron roof and cement walls and floors, although houses
in the poorer settlements are more traditional and
made of bush materials. Modern houses are connected
to the town water and electricity supply (though inter-
ruptions are common) but this is less common in the
settlements [16].
EHPH is the only tertiary healthcare facility in EHP
and caters for all age groups. EHPH has a dedicated
pediatric ward and children’s outpatient facility staffed
by pediatricians, junior medical officers and pediatric
nurses. In addition, urban clinics located in and around
Goroka offer outpatient nurse-led care to children and
adults. EHPH is the only site for inpatient hospital care
in Goroka and surrounding villages and the EHPH chil-
dren’s Outpatient Clinic, North Clinic and Lopi Clinic
are the busiest outpatient facilities in the region.
Children presenting to the Children’s Outpatient
Clinic, EHPH or two smaller urban clinics (North
Clinic, Lopi Clinic) were eligible for recruitment. In
addition, children presenting to the PNG Institute of
Medical Research (PNGIMR) research clinic (located at
the PNGIMR facility in Goroka, next to EHPH) or
already admitted to the EHPH children’s ward were eli-
gible for recruitment. Research was undertaken by
PNGIMR staff.
Recruitment of children with pneumonia and/or
meningitis
Unwell children <5 years of age meeting the inclusion
criteria were eligible for enrolment (see definitions of
moderate and severe pneumonia and clinical meningitis
as described in the PNG clinical manual and used
nationwide [Table 1] [1]). Children not eligible for
enrolment included those with severe congenital abnor-
malities, those hospitalized in the preceding 14 days
and those previously enrolled within 30 days. Prior re-
ceipt of antibiotics was not an exclusion criteria.Eligible children were identified by clinically-trained
research staff using a screening questionnaire. Upon
determining eligibility and obtaining informed consent,
research staff undertook a brief history and examin-
ation before laboratory specimens were obtained and
treatment provided. Verbal consent and minimal data
were obtained initially ensuring timely provision of
appropriate medical care. This was followed by a more
in-depth interview exploring risk factors for disease,
recent antibiotic exposure, vaccination history and
symptoms, examination including oximetry (recorded
using LifeBox Pulse Oximeter, Acare Technology Co.
Ltd, Taiwan), written consent and further specimen col-
lection as required. In addition to parental interview,
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history, co-morbidities and vaccination status.
Children meeting the inclusion criteria yet deemed
well enough for outpatient management were still eli-
gible for enrolment. In addition to children enrolled
through outpatient clinics, inpatients presenting after-
hours were enrolled following parental consent. This
was restricted during the first year of the study to those
identified <48 hours following admission, but was ex-
tended to 96 h to enhance recruitment, particularly for
children with suspected meningitis perceived to be too
sick to undergo an early lumbar puncture.
All admitted cases were reassessed daily during their
hospital stay by clinically trained research staff. Children
deemed well enough to be managed as outpatients were
discharged and reviewed within 48 h. Contact mobile
phone numbers, if available, were collected from all par-
ents prior to discharge. Review of all children residing
within one hour (by vehicle and/or foot) from Goroka
was attempted, 2 to 4 weeks post-discharge. At review,
their health status was assessed and the presence of on-
going symptoms and/or signs confirmed.
Recruitment of controls
Healthy children <5 years of age were enrolled to assist
in determining community vaccination coverage and
for further nasopharyngeal bacterial colonization and
viral studies. Children were eligible if they met the in-
clusion/exclusion criteria (Table 1) and were recruited
during community follow-up visits for discharged cases.
PNGIMR staff conducted community clinics to provide
primary healthcare and vaccination, thereby facilitating
further identification and recruitment of controls.
Given the logistical challenges of recruiting matched
controls, formal case-control matching was not under-
taken although contemporaneous controls were re-
cruited from the same communities as cases. In an
attempt to reduce bias, the number of cases recruited
and median age were regularly assessed and used to
guide targeted control recruitment. Following informed
consent, a brief history and examination was undertaken,
individual health and immunization records were exam-
ined and two nasopharyngeal swabs were collected.
Specimen collection
Consent was sought to collect blood, nasopharyngeal
specimens, urine and (if clinically indicated) CSF from
all cases (Additional file 1: Table S1), and nasopharyn-
geal specimens from controls. Although recommended
in cases of suspected meningitis, a decision to collect
CSF was left to the treating pediatric staff. Using appro-
priate aseptic technique (iodine solution followed by
70% alcohol, ensuring adequate drying time prior to pro-
cedure), PNGIMR research staff collected up to 5 ml ofwhole blood for culture (inoculated directly into BD
BACTEC™ PedsPlus bottles; BD, Franklin Lakes, New
Jersey, United States [US]), PCR and antimicrobial activ-
ity. Blood volume was recorded by clinical staff prior to
blood culture inoculation. Additional blood tests, if
clinically indicated (e.g. malaria blood slides, haemoglo-
bin, human immunodeficiency virus [HIV] serology)
were also obtained. If obtainable, urine was collected
for antimicrobial activity and storage. Two deep-
flocked nasopharyngeal swabs (Copan Diagnostics,
Murrieta, California, US) were collected on all children:
the first placed immediately in 1 ml of skim milk tryp-
tone glucose glycerol broth (STGGB) and the second in
1 ml of viral transport media (VTM). Following initial
processing, STGGB samples were stored at −80 °C
whilst EDTA, serum, urine and VTM samples were
stored at −20 °C. Blood and CSF culture contamination
rates were monitored throughout the study and a
review of collection technique and additional staff
training was undertaken regularly during periods of
higher-than-expected contamination.
Laboratory processing
All laboratory testing was undertaken at the PNGIMR
Bacteriology and Molecular Laboratories, Goroka. Blood
cultures were incubated for up to 5 days at 35 °C using a
BD BACTEC™ automated blood culture system (BD,
Franklin Lakes, NJ) or when unavailable, a 35–37 °C
incubator. Positive bottles (using the BACTEC system)
were subcultured onto standard and selective media and
incubated with/without 5% CO2. During periods when
the BACTEC system was unavailable, manual daily sub-
culture from inoculated BACTEC™ bottles was under-
taken using methods previously described [5]. All CSF
underwent macroscopic examination, manual cell count
and Gram stain. In the setting of CSF pleocytosis, CSF
was cultured on standard media and incubated with/
without 5% CO2, bacterial antigen detection for S.pneu-
moniae and H.influenzae using latex agglutination was
performed and further staining for acid-fast bacilli and
yeast undertaken. CSF biochemistry (protein and glu-
cose) was undertaken using Uristix® reagent urinalysis
strips (Siemens, Victoria, Australia).
Bacterial isolates were identified using colony morph-
ology and standard confirmatory tests (S.pneumoniae:
optochin sensitivity, bile solubility, catalase; H.influen-
zae: differential growth on blood/chocolate agar, X&V
disks). Serotyping was undertaken by the Quellung
reaction using commercially obtained antisera (Staten
Serum Institut, Denmark) and H.influenzae agglutinat-
ing sera (Remel, Dartford, United Kingdom). Anti-
microbial susceptibility testing was conducted on all
clinically relevant isolates by disc diffusion with sus-
pected resistance confirmed by E-tests® (bioMérieux,
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Laboratory Standards Institute (CLSI) breakpoints [17].
For real-time PCR on blood and CSF samples, DNA
was extracted from 200 μl blood/CSF using commer-
cially available kits (Qiagen DNease Blood & Tissue Kit,
Valencia, California, US) and an in-house real-time
PCR for S.pneumoniae (lytA) and H. influenzae (hpd)
performed [18, 19]. In general, replicate samples within
0.5 Cq of each other and with a Cq value ≤35 (but
within the limit of detection as determined by the stan-
dards) were deemed to be positive.
Respiratory virus testing was undertaken using the
dedicated VTM sample and an in-house multiplexed
real-time quantitative PCR assay. DNA/RNA were ex-
tracted using commercially available kits (Qiagen
DNease Blood & Tissue Kit, Valencia, California, US).
Viral targets are described in Additional file 2: Table S2
[20–22]. Semi-quantitative bacterial culture of STGGB
was performed using blood, chocolate, gentamicin-blood
and bacitracin-chocolate agar plates, incubated with 5%
CO2. Bacterial isolates were identified and typed and
susceptibility testing performed as described above.
Antibiotic activity was measured in blood, urine and/
or CSF to better understand the yield of blood and CSF
cultures. This was performed by placing a specimen-
soaked filter paper disk on agar inoculated with a 0.5
MacFarland suspension of Staphylococcus aureus ATCC
25923. Following incubation at 37 °C overnight, a zone
of inhibition was examined and measured.Radiology
When a chest X-ray was requested as part of clinical
care, digital copies were extracted and stored on a dedi-
cated hard drive. These will be reviewed by international
experts using standardised methods [23].Ethics, data and study management and analysis
Ethical approval was obtained from the Institutional
Review Board of PNGIMR (IRB no 1204), the Medical
Research Advisory Committee of PNG (MRAC number
11.29) and the University of Western Australia (RA/4/1/
7960). Clinical and laboratory data were collected on
paper forms, subsequently checked by a second staff
member and entered in a dedicated Filemakerpro data-
base 11 (DB services, Indianapolis, IN, US). Monthly
teleconferences and regular data checks were under-
taken to ensure the accuracy of all data collected.
Analysis was undertaken using SPSS 20.0.0 (IBM Corp,
New York, NY, US). Continuous variables were com-
pared with the Student’s t test, and categorical variables
were compared with χ2 or Fisher’s Exact test. A p value
of ≤0.05 was considered significant.Results
From January 2013 to January 2016, 1001 children with
pneumonia or meningitis and 994 heathy children were
consented to the study. Three cases and 16 controls
were excluded from the analysis as they did not meet
the inclusion criteria (cases: not meeting clinical case
definitions [n = 2]; >5 years of age [n = 1]; controls: evi-
dence of acute respiratory infection [n = 5]; >5 years of
age [n = 11], Table 1). Thirty-four children were enrolled
as cases more than once and 14 controls were subse-
quently enrolled as cases.
Pneumonia and meningitis cases
The median age of enrolled cases was 7.8 months (inter-
quartile range [IQR] 3.9–14.3) and 562/998 cases were male
(56.3%; Table 2). Parents infrequently reported chronic
health concerns (12/984; 1.2%), the most frequent being
chronic respiratory disease (n = 6) and seizures (n = 4).
Ninety-six (9.6%) and 7 (0.7%) cases reported a history of
pneumonia and meningitis, respectively.
Case enrolment during the study increased from 286
cases in 2013 to 421 in 2015 (Table 2). Despite the sea-
sonal nature of pneumonia (peak activity during the
southern hemisphere winter), cases were recruited year
round: the average number of cases recruited per month
was 36 (range 9–61; Fig. 1). A significant proportion of
cases were recruited following admission to EHPH (404/
998; 40.5%) with the remainder recruited from the
EHPH outpatient clinic (313; 31.4%), community (201;
20.1%) or PNGIMR research clinics (75; 7.5%). The pro-
portion of children recruited prior to admission to hos-
pital (i.e. from EHPH outpatients or community clinics,
as opposed to the EHPH children’s ward) increased
over the duration of the study. This shift in recruitment
was part of a dedicated focus to enhance recruitment of
children prior to antibiotic delivery (2013: 30.8% re-
cruited prior to admission to EHPH, 2014: 58.1%, 2015:
80.1%; p < 0.0001).
The most frequent diagnosis was moderate pneu-
monia (n = 784, 78.6%), followed by severe pneumonia
(n = 187, 18.7%) and suspected meningitis (with or
without pneumonia; n = 75, 7.5%). Nasopharyngeal
samples were collected on all cases with blood obtain-
able from 987 children (98.9%; Table 2). The volume
of blood collected per patient increased throughout
the study period: mean volume in 2013, 1.36 ml; 2014,
1.49 ml; 2015, 1.95 ml; difference in means; 0.12 ml,
(95% confidence interval [CI]: 0.016–0.224; p <0.03)
and 0.46 ml (95%CI: 0.32–0.61; p < 0.0001), respect-
ively. In addition, the number of children with dedi-
cated EDTA samples increased over time: 2013, 89/
286 (31.1%); 2014, 150/291 (51.5%) and 2015, 273/421
(64.8%), p < 0.001. The rate of contaminated blood
cultures decreased during the study: 2013, 63/281
Table 2 Cases and controls: demographics, recruitment,
diagnosis, diagnostic specimens and follow up
Cases: n (%)
(n = 998)
Controls: n (%)
(n = 978)
Demographics
Median age (months; IQR) 7.8 months
(3.9–14.3)
20.8 months
(8.2–36.4)
Male sex (%) 562 (56.3%) 520 (53.2%)
Recruitment year
2013 286 (28.6%) 172 (17.6%)
2014 291 (29.1%) 288 (29.4%)
2015a 421 (42.2%) 518 (53.0%)
Recruitment site
Children’s ward, EHPH 404 (40.5%) NA
Outpatient clinics, EHPH 313 (31.4%)
North Clinic 194 (19.4%)
Lopi Clinic 7 (0.7%)
PNGIMR Research Clinic 75 (7.5%)
Unknown 5 (0.5%)
Diagnosis
Moderate pneumonia
• Without suspected meningitis
• With suspected meningitis
784 (78.6%)
753
31
NA
Severe pneumonia
• Without suspected meningitis
• With suspected meningitis
187 (18.7%)
170
17
Suspected Meningitis
(without pneumonia)
27 (2.7%)
Diagnostic specimens collected
Blood culture 987 (98.9%) NA
EDTA blood 512 (51.3%) NA
Serum 363 (36.4%) NA
CSF 31 (3.12%) NA
Nasopharyngeal swab 998 (100%) 978 (100%)
Urine 42 (4.2%) NA
Successful follow up
(of eligible children) by year
2013 156/223b (69.9%) NA
2014 162/209b (77.5%)
2015a 251/310b (81.0%)
Abbreviations: IQR interquartile range, EHPH Eastern Highlands Provincial
Hospital, NA not applicable
a inclusive of the first 3 weeks of January 2016
b denominator is children residing within 1 h by vehicle from Goroka
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(11.4%), p < 0.001. Collection of blood prior to antibi-
otics was also more frequently achieved over the
course of the study: 2013, 139/275 (50.5%); 2014, 198/
282 (70.2%) and 2015, 246/415 (83.4%), p < 0.001.
Both CSF and urine samples were infrequently col-
lected during the study. In children with a clinicaldiagnosis of suspected meningitis (n = 75), only 29
underwent a CSF examination. Of the remainder, 24
cases were deemed by EHPH medical staff not to have
clinical evidence of meningitis, seven cases had contra-
indication to lumbar puncture and eight had a lumbar
puncture without CSF being obtained. In a further seven
cases with suspected meningitis, it is uncertain why sam-
pling was not performed. A further 2 CSF samples were
taken from children not meeting the clinical definition
of meningitis.
Half the patients were admitted to hospital (500/998;
50.1%) with the remainder managed as outpatients. Less
than 25% of children had an X-ray performed. The me-
dian length of hospital stay was 2 days (IQR 2–5).
Eighteen deaths were identified (overall case fatality
rate (CRF): 18/998, 1.8% overall; pneumonia, 1.5%; men-
ingitis, 8.0%). The in-hospital CFR was 14/500 (2.8%
overall: pneumonia, 2.3%; meningitis 8.7%). Follow-up
was attempted in children residing within 1 h by vehicle
from Goroka (n = 742). Outcome data was obtained on
569 children (76.7%). During the period of the study, the
proportion of eligible children that were successfully
followed up increased from 69.9% (2013) to 81.0%
(2015), p < 0.02.
Controls
The median age of enrolled controls was 20.8 months
(IQR 8.2–36.4) and 522/983 enrolled controls were male
(53.2%; Table 2). Successful recruitment of controls in-
creased during the study period, particularly following
the institution of dedicated clinics in 2014 and 2015.
Despite ongoing attempts to recruit younger controls,
controls remained significantly older than cases through-
out the study; median ages cases vs. controls: 6.6 vs.
14.3 months (2013), 9.3 vs. 22.7 months (2014) and 8.4
vs. 21.0 months (2015).
Vaccination coverage
Child health books that included vaccination status were
assessable in 991 cases (99.3%) and 976 controls (99.8%).
Coverage for one dose of DTPw-HepB-Hib in children
>1 month of age was 65.5% in cases and 71.9% in con-
trols (p < 0.01, Fig. 2), falling for three doses in children
>3 months of age to 31.6% in cases and 43.3% in con-
trols (p < 0.001). The significant difference in vaccine
coverage between cases and controls remained when re-
stricted to children < 12 months of age at enrolment.
The overall median age of the first, second and third
dose of DTPw-HepB-Hib was 1.4 months (IQR 1.1–3.0),
3.1 months (IQR 2.1–6.1) and 4.7 months (IQR 3.1–8.0).
During the study, vaccine coverage significantly im-
proved: three dose DTPw-HepB-Hib coverage in chil-
dren >3 months of age increased from 14.9 to 43.0% in
cases and 29.0 to 47.7% in controls (p < 0.001 in both).
Fig. 1 Enrolment of cases and controls by month: January 2013 to January 2016
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vaccine was not available in the EHP until 2015. The
2015 coverage of PCV13 was low in both cases and con-
trols with only 25.4 and 24.4% of cases and controls
>1 month receiving one dose, and 4.0 and 6.5% of cases
and controls >3 months receiving three doses (no sig-
nificant difference between cases and controls).
Discussion
The ongoing burden of childhood disease in PNG neces-
sitates a contemporary reassessment of pneumonia and
meningitis etiology and outcomes. Given the lack of ac-
cess to and (if present) underutilisation of the microbio-
logical laboratory in PNG, targeted projects using
routine and contemporary diagnostics are required to
assess the current pathogen-specific burden of disease.Fig. 2 Vaccine coverage by case-control status and age (*PCV13 data for 2These data are essential to assess potential benefits of
childhood vaccination and to identify potential changes
in etiology.
Undertaking such studies, particularly in locations
such as the highlands of PNG, pose unique challenges in
study design, recruitment, specimen handling and la-
boratory practice. A number of these challenges are
unique to both PNG and to other isolated highland
communities, while others are frequent with any large
prospective study. This paper outlines the methods and
challenges observed in recruiting nearly 2000 children
over 3 years.
Based on existing EHPH service data, the study pro-
posed to recruit >1000 children with clinical pneumonia
and meningitis over 2 years. Prior to commencement,
concern was raised by the community about the invasive015 only)
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history of community engagement developed over many
successful research studies. Regular visits to communi-
ties to discuss this study, explaining the routine nature
of specimen collection in other healthcare settings and
the collaborative nature of healthcare provided by
PNGIMR and hospital staff was essential in the early
phase of the study. The provision of non-monetary in-
centives such as transport from hospital to home for
study participants and future access to the PNGIMR
clinic are also likely to have assisted with recruitment,
which improved throughout the study.
Barriers to recruitment included frequent and some-
times prolonged industrial action leading to closure of
health facilities. As a result, lower numbers of children
were admitted to the ward and at times, PNGIMR staff
needed to focus on providing healthcare rather than the
research project. Outbreaks of vaccine preventable dis-
eases (e.g. an outbreak of measles in April to June 2015)
required additional healthcare resources to be diverted
away from research activities. Hospital senior and junior
medical staff changed several times during the 3-year
study period and a lack of familiarity with the study re-
quired regular re-engagement by the research team with
the EHPH paediatric staff. Significant variation in prac-
tice, especially with CSF collection and utilisation of
radiology were noted throughout the study. As both pro-
cedures were not mandated, rather recommended based
on clinical need, it is likely that physician preference
contributed to variable utilisation. Provision of a dedi-
cated study doctor may have assisted with the variation
in practice observed.
Compared with previous pneumonia studies con-
ducted at EHPH [8], a number of differences should be
noted: a lower proportion of enrolled children had se-
vere pneumonia (19% of the pneumonia cohort in this
study vs 46% in Barker et al. [8]). A higher number were
deemed well enough to manage as outpatient following
initial treatment (50% vs 0% in Barker et al. [8]). Forty
per cent of children were enrolled from the ward follow-
ing initial management by EHPH staff, albeit in decreas-
ing numbers over the duration of the study. A
significant number of children had been administered
antibiotics even prior to their first interview at EHPH
(data not shown). It is expected that these factors will
reduce the rate of detection of bacteraemia and invasive
bacterial isolates from the current cohort. The in-
hospital mortality rate (2.8%) is significantly lower than
Barker et al. (8%) [8] and the rate reported nationally
(5.2%) by the Paediatric Hospital Reporting (PHR) sys-
tem, yet comparable to 2013 PHR data collected from
EHPH (2.4%) [4]. These severity of illness and mortality
data are encouraging and suggest that, compared with
past studies, improvements in access to health services,earlier recognition of childhood pneumonia with earlier
institution of antimicrobial therapy and supportive care
are leading to better outcomes for children with
pneumonia.
Recruitment of controls was challenging, particularly
in the early phases of the study. Despite regular visits to
rural and peri-urban communities, well children (par-
ticularly those < 6 months of age) were often absent, fre-
quently accompanying their parents to the fields early in
the morning. There was an attempt to overcome this by
scheduling PNGIMR community clinics and establishing
age specified targets. Following institution of these
clinics, larger numbers of controls were recruited, yet re-
cruitment of younger controls remained an ongoing
challenge. Given the uneven balance between cases and
controls, assessment of biological samples (e.g. nasopha-
ryngeal samples) will be undertaken in cases and con-
trols matched post-enrolment by month of illness, age
and village.
PNG has a long history of utilization of a hand-held
child health record. Documentation of vaccination status
is routinely recorded in the health book (on the reverse
of front cover and in the continuous clinical records).
The health record was assessable in more than 99% of
cases and controls. The variable nature of recording re-
quired additional training and care to ensure accuracy of
the data collected by the research team. This may have
resulted in underestimation of the vaccine coverage early
in the study. Replacement of lost hand-held records or
an older child having more than one book may result in
underestimation of vaccine uptake (data not presented).
Despite this, the record provides a unique opportunity
to assess uptake of vaccination status in a country where
access to electronic or manually collected vaccine distri-
bution data remains a challenge. Vaccine coverage in the
highlands remains lower than the reported national aver-
age [2]: the reasons for this are likely to be multifactorial
and may include reduced access to health services given
the remoteness of highland villages, problems with con-
sistent immunization supply and parental education with
ongoing mistrust of infant immunization. Increased vac-
cine coverage is encouraging and suggests that targeted
programs including the Special Integrated Routine EPI
Strengthening Program (SIREP) is having an impact in
the PNG highlands.
Undertaking a study dependent on key infrastructure
in isolated locations poses unique challenges. For much
of the study the BD BACTEC™ Instrumented Blood Cul-
ture System was not working, despite multiple attempts
by the laboratory staff and the manufacturer to repair
the machine both in Goroka and Port Moresby. The la-
boratory was reliant on manual subculture of blood cul-
tures increasing the time and risk of contamination of
critical specimens. Higher rates of contamination are
Blyth et al. Pneumonia  (2017) 9:5 Page 9 of 10likely to impact on the ability to detect significant bacter-
aemia. For significant periods of time, the hospital X-ray
facility required repairs, meaning that physician-requested
X-rays were not available. These key challenges must be
considered when designing studies in third-world settings,
particularly in locations outside the nation’s capital city
with difficult access by road or by air.
Achieving a follow up rate of >75% in an environment
where formal town maps and permanent phone connec-
tions are largely non-existent is a testament to both
study participants and staff. This was achieved by me-
ticulous documentation of village, hamlet and house lo-
cation and use of PNGIMR drivers to return children
and their parents to their homes. This was also en-
hanced by the provision of ongoing healthcare clinics in
larger villages and access for study participants to the
PNGIMR clinic. Despite these incentives, numerous at-
tempts were often required for follow up.
Conclusions
In summary, recruitment of large numbers of pediatric
pneumonia and meningitis cases and community controls
in a third-world setting with limited health services, health
and other infrastructures presents unique challenges. The
study successfully enrolled 998 cases and 978 controls, ob-
tained comprehensive clinical data and biological speci-
mens, and was able to follow up >75% following discharge.
Furthermore, staff documented increasing coverage of
pneumococcal and Hib conjugate vaccines in PNG children.
Key aspects to overcoming the challenges of conducting
research in third-world settings include a pragmatic and
flexible study design and strong collaborative relationships
with healthcare providers. Prior to commencing research,
the infrastructure needs of the study (and alternative plans
should key equipment be unavailable) must be considered.
Ongoing community engagement is paramount to optimize
recruitment and translation. In addition, the provision of
ongoing training for both research and clinical staff ensures
staff retention and facilitates translation of research findings
into changes in clinical practice.
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